GELS

Business Context and Reporting Period

Gelteq Ltd (GELS) is an Australian public company incorporated in 2018, listed on the Nasdaq Capital Market. The company develops and commercializes white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports nutrition. This summary covers the fiscal year ended June 30, 2024, as reported in the Form 20-F Annual Report.

Key Financial Metrics

Note: The filing does not provide explicit gross margin percentages due to zero revenue in 2024. Intangible assets comprised 98.6% of total assets as of June 30, 2024.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in FY2024 from AUD$79,843 in FY2023. This was due to delays in manufacturing and delivery of orders caused by customer cash flow difficulties and supply chain issues. No revenue was recognized for undelivered orders.
• Expense Reduction: Research expenses decreased by approximately 58% (AUD$388,978) due to a strategic shift toward setting up new laboratory facilities rather than external product testing. Corporate expenses remained relatively flat.
• Inventory Write-off: The company wrote off all inventory (AUD$95,201) as the shelf life had expired by June 30, 2024.
• Debt Structure: Borrowings increased significantly to AUD$3.84 million (from AUD$2.48 million) due to the issuance of new convertible notes and shareholder loans. Current liabilities increased sharply as shareholder loans were reclassified as current due to maturity dates.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Post-IPO Liquidity: Subsequent to the reporting period, Gelteq consummated its Initial Public Offering (IPO) on October 30, 2024, raising approximately USD$5.2 million (AUD$7.95 million).
• Revenue Recognition: Management expects to recognize revenue from deferred orders (approximately 400,000 units) in the fiscal year ending June 30, 2025, pending resolution of customer cash flow issues.
• Strategic Focus: The company is prioritizing pharmaceutical research via the FDA 505(b)(2) pathway and expanding sales in animal health and nutraceutical verticals.

Risks and Contingencies

• Going Concern: The auditors included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and a current liability position. This was mitigated by the post-period IPO and loan extensions.
• Customer Concentration & Cash Flow: Significant revenue is dependent on a few customers who have historically delayed payments due to their own cash flow difficulties.
• Intangible Asset Impairment: With 98.6% of assets being intangible, the company relies on high projected revenue growth (approx. 92% annually) to justify asset values. Failure to meet these projections could trigger impairment charges.
• Regulatory Approval: Future growth in the pharmaceutical vertical depends on obtaining FDA approvals, which are uncertain and costly.

Investor Verification Checklist

• Customer Solvency: Verify the financial status of key customers holding deferred revenue to assess the likelihood of order fulfillment in FY2025.
• Intangible Asset Valuation: Review the assumptions in the discounted cash flow model used to justify the AUD$20.4 million intangible asset carrying value, specifically the projected revenue growth rates.
• Post-IPO Cash Utilization: Monitor the deployment of the USD$5.2 million IPO proceeds to ensure it covers the working capital deficit and funds the planned FDA 505(b)(2) clinical trials.
• Debt Maturity: Confirm the terms of the shareholder loans and convertible notes, noting that while extended to December 2025, they carry interest rates of 6-12%.
• Revenue Recognition Policy: Scrutinize the timing of revenue recognition for future orders to ensure it aligns with delivery and payment receipt, given the history of delays.